CTX-III (nordicCTX-III™)
PopularA cross-linked fragment of type III collagen generated by matrix metalloproteinase activity, enabling non-invasive assessment of fibrolysis and fibrosis resolution.
Key features and values
- Measures degradation fragments of type III collagen formed by matrix metalloproteinase activity.
- Reflects the dynamics of extracellular matrix remodeling and tissue turnover.
- Provides quantitative assessment of fibrotic and connective tissue degradation.
- Applicable to studies of fibrotic, inflammatory, and degenerative conditions.
- Enables monitoring of disease progression and resolution in connective tissue disorders.
- Supports evaluation of therapeutic interventions targeting tissue remodeling.
- Facilitates research into mechanisms underlying fibrosis and matrix turnover.
Description
The CTX-III biomarker assay quantifies neo-epitope fragments of type III collagen generated through matrix metalloproteinase-mediated cleavage, providing a specific measure of extracellular matrix degradation. This assay enables the assessment of fibrotic activity and tissue remodeling across a range of pathological states characterized by increased connective tissue turnover. By capturing changes in type III collagen breakdown, CTX-III supports research and therapeutic development in conditions where fibrosis, inflammation, or extracellular matrix reorganization are central to disease mechanisms.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
